| abstract |
The present invention relates to pharmaceutical compositions comprising a therapeutically effective dose of an isolated interferon (IFN) or IFN mutein for treatment of cardiomyopathy and of endothelial dysfunction, and to methods of treating cardiomyopathy and methods of treating endothelial dysfunction using such pharmaceutical compositions. Particularly, the pharmaceutical compositions of the present invention comprise a therapeutically effective dose of an isolated, human IFN, or IFN mutein that is a variant of an isolated human IFN., e.g. , an isolated, native, human IFNß or an isolated, native, human IFNα. |